Tracer shows promise for imaging of prostate tumors

11/7/2013 | MolecularImaging.net

F-18 aluminum-fluoride radiolabeled bombesin analog NODAGA-RM1 showed strong cancer-imaging properties and serum stability compared with Cu-64 NODAGA-RM1, making it a potentially effective tool for PET imaging of prostate cancer. The F-18 AlF-NODAGA-RM1 tracer binds to gastrin-releasing peptide receptors and had a higher tumor uptake value of 4.6 at 30 minutes, 4.0 at one hour and 3.9 at two hours, according to results of a comparative study published in the Journal of Nuclear Medicine.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY